KNIPPELS, Leon Matthieu Johannes (Noordeindestraat 31, VJ Utrecht, NL-3523, NL)
NAUTA, Alma Jildou (Fuut 3, RD Driebergen, NL-3972, NL)
GARSSEN, Johan (Zandoever 1, DA Nieuwegein, NL-3433, NL)
BEN AMOR, Kaouther (Oudegracht 401CK, PH Utrecht, NL-3511, NL)
KNIPPELS, Leon Matthieu Johannes (Noordeindestraat 31, VJ Utrecht, NL-3523, NL)
NAUTA, Alma Jildou (Fuut 3, RD Driebergen, NL-3972, NL)
GARSSEN, Johan (Zandoever 1, DA Nieuwegein, NL-3433, NL)
| CLAIMS 1 Use of a composition comprising Bifidobacterium breve for the manufacture of a nutritional composition for prevention of cat allergy in a human subject. 2 The use according to claim 1 wherein the prevention takes place when said human subject has reached an age above 12 months, more preferably above 16 months. 3 The use method according to any one of the preceding claims wherein the nutritional composition is administered to a human subject with an age between 0 and 12 months, more preferably between 0 and 6 months. 4 The use according to any one of the preceding claims wherein the nutritional composition is administered for a period of at least 4 weeks, more preferably at least 8 weeks. 5 Use of a composition comprising Bifidobacterium breve for the manufacture of a nutritional composition for reducing the increase of total serum IgE concentrations in a human subject when said human subject has reached an age above 12 months, wherein the nutritional composition is adminstered for a period of at least 4 weeks when said human subject has an age between 0 and 12 months. 6 The use according to claim 6, wherein the human subject at an age between 0 and 12 months is IgE negative. 7 The use according to any one of the preceding claims wherein said human subject to which the nutritional composition is administered suffers from dermatitis and/or eczema. 8 The use according to any one of the preceding claims wherein the composition comprises at least lxl 05 cfu the B. breve per g dry weight. 9 The use according to any one of the preceding claims wherein the B. breve is B. breve M16-V. The use according to any one of the preceding claims wherein the nutritional composition further comprises non-digestible oligosaccharides selected from the group consisting of fructo-oligosaccharides, galacto-oligosaccharides, gluco-oligosaccharides, arabino- oligosaccharides, mannan-oligosaccharides, xylo-oligosaccharides, fuco- oligosaccharides, arabinogalacto-oligosaccharides, glucomanno-oligosaccharides, galactomanno-oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligosaccharides. The use according to claim 10 wherein the nutritional composition comprises galacto- oligosaccharides and/or fructo-oligosaccharides. The use according to claim 10 or 11 wherein the nutritional composition comprises more than 0.25 wt.% of non-digestible oligosaccharides based on dry weight. The use according to any one of the preceding claims wherein the nutritional composition comprises i. lxlO5 cfu to lxlO10 cfu B. breve per g dry weight, and either ii. 0.5 to 20 wt.% galacto-oligosaccharides based on dry weight or iii. 0.05 to 2 % fructo-oligosaccharides based on dry weight or both ii. and iii. The use according to any one of the preceding claims wherein the nutritional composition comprises lipid that provides 5 to 50% of the total calories, protein that provides 5 to 50% of the total calories, and carbohydrate that provides 15 to 90% of the total calories. The use according to any one of the preceding claims wherein the amount of nutritional composition administered per day is at least 50 ml. |
FIELD OF THE INVENTION
The invention relates to infant nutrition comprising probiotics which has long term effects on the immune system, in particular on IgE levels and cat allergy, going beyond the time the composition has been administered.
BACKGROUND OF THE INVENTION
Over the past decades, the prevalence of IgE mediated allergic diseases has risen in western countries. This increase has been hypothesized to result from diminished microbial exposure, leading to an altered composition of the intestinal microbiota. It has been shown that intestinal microbiota composition differs between children with and without atopy.
Several randomized controlled trials have been performed to investigate if intestinal microbiota manipulation with probiotics, living micro-organisms with immunomodulatory effects, reduce the severity of atopic dermatitis (AD). Children with AD have a chance of approximately 40% to develop asthma later in childhood, compared to 5-10% in the general population. Since AD is often the starting point of the so-called atopic march, probiotics may bring the atopic march to a halt in these children.
In Kuitinen et al, 2009, J Allerg Clin Immunol 123: 335-341 administration of of a mix of four probiotic strains and galacto -oligosaccharides in high risk infants did not have an overall effects on IgE-associated diseases, except in the subgroup of C-section born infants regarding food allergy (positive SPT response and/or food-specific IgE > 0.7) and IgE-associated eczema. In Kukkonen et al, 2007 J Allergy Clin Immunol. 2007 Jan; l 19(1): 192-8, at the age of 2 years no effects of early administration of a mix of four probiotic strains and galacto-oligosaccharides were observed on the total of IgE associated diseases, except in the subgroup of IgE infants with positive skin prick test responses or serum antigen-specific IgE levels of greater than 0.7 kU/L. The geometric mean serum total IgE level was 25.7 kU/L) in the probiotic group and 27.2 kU/Lin the placebo group (probiotic/placebo ratio, 0.95; 95% CI, 0.76-1.18). US 2006/233772 discloses the perinatal use of L GG for preventing or reducing the production of serum IgE antibodies in a subject, the method comprising prenatally administering and/or postnatally administering to the subject a therapeutically effective amount of L GG. WO 2008/153391 discloses the use of inactivated B. breve and a mix of non-digestible oligosaccharides for amongst others treatment and/or prevention of asthma.
SUMMARY OF THE INVENTION
The inventors have surprisingly found that children, who had been administered a probiotic composition comprising B. breve during infancy, had a statistically significant lower specific IgE against cat allergens when examined during a follow up later in life, than those children who had been administered a placebo during infancy. These results indicate that this specific probiotic composition has a preventive effect on cat allergy. Furthermore, the change in total serum IgE concentration between one year follow-up and baseline was lower in the probiotic than in the placebo group. This effect was especially prevalent in the subgroup of children that were IgE-negative (i.e. had low serum IgE levels) during infancy. DETAILED DESCRIPTION OF THE INVENTION
The present invention thus concerns a method for prevention and/or treatment of cat allergy in a human subject, the method comprising administering to said human subject a nutritional composition comprising Bifidobacterium breve. In other words the present invention concerns the use of a composition comprising Bifidobacterium breve for the manufacture of a nutritional composition for prevention and/or treatment of cat allergy in a human subject.
The invention can also be worded as a nutritional composition comprising Bifidobacterium breve for prevention and/or treatment of cat allergy in a human subject. Preferably the present method or use or compoisition is for prevention of cat alleergy in a human subject.
The invention also concerns a method for reducing the increase of total serum IgE concentrations in a human subject when said human subject has reached an age above 12 months, the method comprising administering to said human subject a nutritional composition comprising Bifdiobacterium breve for a period of at least 4 weeks when said human subject has an age between 0 and 12 months. In other words the present invention concerns the use of a composition comprising Bifidobacterium breve for the manufacture of a nutritional composition for reducing the increase of total serum IgE concentrations in a human subject when said human subject has reached an age above 12 months, wherein the nutritional composition is adminstered for a period of at least 4 weeks when said human subject has an age between 0 and 12 months.
The invention can also be worded as a nutritional composition comprising Bifidobacterium breve for reducing the increase of total serum IgE concentrations in a human subject when said human subject has reached an age above 12 months, wherein the nutritional composition is adminstered for a period of at least 4 weeks when said human subject has an age between 0 and 12 months.
The method or use or composition for reducing the increase of total serum IgE is preferably in a human subject that is IgE negative at an age between 0 and 12 months. IgE negative at an age between 0 and 12 months preferably means that a human subject has an IgE serum level below 5 kU/L at an age < 3 months and below 15 kU/L at an age > 3 months.
Bifidobacterium breve
The present composition comprises Bifidobacterium breve. Bifidobacterium breve is a Gram- positive, anaerobic, branched rod-shaped bacterium. The present B. breve preferably has at least 95 % identity of the 16 S rR A sequence when compared to the type strain of B. breve ATCC 15700, more preferably at least 97% identity (Stackebrandt & Goebel, 1994, Int. J. Syst. Bacteriol. 44:846-849). Preferred B. breve strains are those isolated from the faeces of healthy human milk- fed infants. Typically, these are commercially available from producers of lactic acid bacteria, but they can also be directly isolated from faeces, identified, characterised and produced. According to a preferred embodiment, the present composition contains at least one B. breve selected from the group consisting of B. breve Bb-03 (Rhodia/Danisco), B. breve M-16V (Morinaga), B. breve R0070 (Institute Rosell, Lallemand), B. breve BR03 (Probiotical), B. breve BR92) (Cell Biotech), DSM 20091, LMG 1 1613, YIT4065, FERM BP-6223 and CNCM 1-2219. Most preferably, the B. breve is selected from the group consisting of B. breve M-16V and B. breve CNCM 1 -2219. The present composition preferably contains 10 2 to 10 13 colony forming units (cfu) B. breve per gram dry weight of the present composition, preferably 10 4 to 10 12 , more preferably 10 5 to 10 10 , most preferably from 10 5 to lxl 0 9 cfu B. breve per gram dry weight of the present composition. The dose of B. breve according to the present invention is preferably administered at a daily dose of i 2 13 , more preferably from 105 to 1012 , most preferably from 108 to 5x1010
(r to 10 colony
3 13
forming units (cfu). Preferably the composition comprises 10 to 10 cfu B. breve per 100 ml, more preferably 10 6 to 10 11 cfu B. breve per 100 ml, most preferably 10 7 to 10 10 cfu B. breve per 100 ml.
The present composition preferably comprises viable B. breve. Alternatively, the present composition preferably comprises non-viable B. breve equivalent to the amounts of CFU as described above. The equivalent of cfu can be determined by performing the 5 'nuclease assay with the B. breve probes and primers as disclosed in WO 2005/039319 in the product (i.e. an infant formula) comprising non-viable B. breve and compare this with a calibration curve obtained from a comparable product (for instance a standard infant formula) to which known amounts in cfu of viable, preferably dried, B. breve have been added. The dried viable bifidobacteria can be commercially obtained as described above. B. breve cells can be made nonviable by methods known in the art, including heat treatment steps (including sterilization, pasteurization, UHT treatment), radiation (UV), treatment with oxygen, treatment with bactericidals such as ethanol, sonication, ultra high pressure application, high pressure homogenization and use of a cell disruptor. Preferably the B. breve is heat-killed. The presence of non-viable B. breve advantageously provides many product technological benefits, including increased shelf-life, a reduced incidence of bacterial contamination, decreased post-acidification of the product, improved dosage control and improved convenience of reconstitution.
The B. breve of the present invention is preferably not genetically modified. Genetic modification is disadvantageous with respect to safety and consumer acceptance. Furthermore, genetic modification is costly and usually negatively affects strain growth properties.
Non-digestible oligosaccharides
Preferably the present composition comprises non-digestible oligosaccharides with a degree of polymerization (DP) between 2 and 250, more preferably 3 and 60. Non-digestible oligosaccharides further support the preventive effect on asthma later in life and on asthma medication. These effects are synergistic. The term "oligosaccharide" as used in the present invention preferably refers to a saccharide with a degree of polymerization (DP) of 2 to 250, preferably a DP 2 to 100, more preferably 2 to 60. It is understood that in the context of this invention a saccharide with a DP in a certain range may include a mixture of saccharides with different average DP's, for example, if an oligosaccharide with a DP of 2 to 100 is included in the present composition, this may include compositions which contain oligosaccharides with an average DP between 2 and 5, an average DP between 50 and 70 and an average DP between 7 and 60. The term "non-digestible oligosaccharide" as used in the present invention refers to oligosaccharides which are not or only partially digested in the intestine by the action of acids or digestive enzymes present in the human upper digestive tract (small intestine and stomach) but which are fermented by the human intestinal flora. For example, sucrose, lactose, maltose and maltodextrins are considered digestible. For example, galacto-oligosaccharides, fructo- oligosaccharides are considered non-digestible oligosaccharide.
The non-digestible oligosaccharide is preferably selected from the group consisting of fructo- oligosaccharides (such as inulin), galacto-oligosaccharides (such as transgalacto- oligosaccharides or beta-galacto-oligisaccharides), gluco-oligosaccharides (such as gentio-, nigero- and cyclodextrin-oligosaccharides), arabino-oligosaccharides, mannan-oligosaccharides, xylo-oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno- oligosaccharides, galactomanno-oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligosaccharides. Preferably the composition comprises gum acacia on combination with a non-digestible oligosaccharide.
Preferably the present composition comprises fructo-oligosaccharides and/or galacto- oligosaccharides, more preferably galacto-oligosaccharides, most preferably transgalacto- oligosaccharides. In a preferred embodiment the composition comprises a mixture of transgalacto -oligosaccharides and fructo-oligosaccharides. Preferably the present composition comprises galacto-oligosaccharides with a DP of 2-10, preferably with an average DP between 2 and 10, and/or fructo-oligosaccharides with a DP of 2-60, preferably with an average DP between 2 and 60, preferably with an average DP between 10 and 60, preferably with an average DP between 20 and 60. Preferably the composition comprises galacto-oligosaccharides and fructo-oligosaccharides in a weight ratio of 20 to 0.5, more preferably 20 to 1 , most preferably from 12 to 2. The galacto-oligosaccharide is preferably selected from the group consisting of transgalacto- oligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT. In a particularly preferred embodiment the present method comprises the administration of transgalacto -oligosaccharides ([galactose] n -glucose; wherein n is an integer between 1 and 60, i.e. 2, 3, 4, 5, 6, 59 ,60; preferably n is selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10). Transgalacto-oligosaccharides (TOS) are for example sold under the trademark Vivinal™ (Borculo Domo Ingredients, Netherlands). Preferably the saccharides of the transgalacto-oligosaccharides are β-linked.
The present composition preferably contains fructooligosaccharide. The term "fructo- oligosaccharide" as used herein refers to a non-digestible polysaccharide comprising a chain of at least 2 β-linked fructose units, with a DP of 2 to 250, preferably 7 to 100, more preferably 20 to 60. Preferably inulin is used. Inulin is for example available under the tradename "Raftilin HP ® ", (Orafti). The average DP of the present fructo-oligosaccharide is preferably at least 7, more preferably at least 10, preferably below 100. The fructo-oligosaccharide used preferably has the (majority of) fructose units linked with a β(2— 1) linkage. Other terms for fructooligosaccharides include inulin, fructopolysaccharide, polyfructose, fructans and oligofructose. The present composition preferably comprises fructo-oligosaccharides with a DP of 2 to 200.
Preferably, the composition comprises of 80 mg to 2 g non-digestible oligosaccharides per 100 ml, more preferably 150 mg to 1.50 g, even more preferably 300 mg to 1 g per 100 ml. Based on dry weight, the composition preferably comprises 0.25 wt.% to 20 wt.%, more preferably 0.5 wt.% to 10 wt.%, even more preferably 1.5 wt.% to 7.5 wt.% non-digestible oligosaccharides. A lower amount of non-digestible oligosaccharides will be less effective in decreasing IgE levels and cat allergy later in life, whereas a too high amount will result in side-effects of bloating and abdominal discomfort.
2 13
Preferably the composition comprises 10 to 10 cfu B. breve per gram and 0.25 wt.% to 20 wt.% non-digestible oligosaccharides based on dry weight, more preferably 10 5 to 10 10 cfu B. breve per gram and 0.5 wt.% to 10 wt.% non-digestible oligosaccharides based on dry weight.
3 13
Preferably the composition comprises 10 to 10 cfu B. breve and 80 mg to 2 g non-digestible oligosaccharides per 100 ml, more preferably 10 6 to 10 11 cfu B. breve and 300 mg to 1 g non- digestible oligosaccharides per 100 ml.
Preferably the nutritional composition comprises i) lxlO 5 cfu to lxlO 10 cfu B. breve per g dry weight, more preferably lxlO 6 cfu to lxlO 10 cfu; and either ii) 0.5 to 20 wt.% galacto- oligosaccharides based on dry weight, more preferably 0.5 to 10 wt.% galacto-oligosaccharides or iii) 0.05 to 2 % fructo-oligosaccharides based on dry weight, more preferably 0.1 to 1 wt.% fructo-oligosaccharides or both ii) and iii).
Compositions
The present composition is preferably enterally administered, more preferably orally.
The present composition is preferably a nutritional formula, preferably an infant formula. The present composition can advantageously be applied as a complete nutrition for infants. The present composition preferably comprises lipid, protein, and carbohydrate and is preferably administered in liquid form. The present invention includes dry compositions, e.g. powders, which are accompanied with instructions as to admix said dry compositions, in particular nutritional formula, with a suitable liquid, e.g. water.
The present invention advantageously concerns a composition wherein the lipid provides 5 to 50% of the total calories, the protein provides 5 to 50% of the total calories, and the carbohydrate provides 15 to 90% of the total calories. Preferably, in the present composition the lipid provides 35 to 50% of the total calories, the protein provides 7.5 to 12.5% of the total calories, and the carbohydrate provides 40 to 55% of the total calories. For calculation of the % of total calories for the protein component, the total of energy provided by the proteins, peptides and amino acids needs to be taken into account.
The present composition preferably comprises at least one lipid selected from the group consisting of animal lipid (excluding human lipids) and vegetable lipids. Preferably the present composition comprises a combination of vegetable lipids and at least one oil selected from the group consisting of fish oil, animal oil, algae oil, fungal oil, and bacterial oil. The present composition comprising non-digestible oligosaccharides excludes human milk. The protein component used in the nutritional preparation are preferably selected from the group consisting of non-human animal proteins (preferably milk proteins, preferably proteins from cow's milk), vegetable proteins (preferably soy protein and/or rice protein), free amino acids and mixtures thereof. The present composition preferably contains casein, whey, hydrolysed casein and/or hydrolysed whey protein. Preferably the protein comprises intact proteins, more preferably intact bovine whey proteins and/or intact bovine casein proteins. As the present composition is preferably suitably for use by infants suffering from allergy, the protein is preferably selected from the group consisting of hydro lyzed milk protein, more preferably hydro lyzed whey protein.
The liquid nutritional composition preferably has a caloric density between 0.1 and 2.5 kcal/ml, even more preferably a caloric density of between 0.5 and 1.5 kcal/ml, most preferably between 0.6 and 0.8 kcal/ml. The amount of nutritional composition administered per day is preferably between 50 and 2000 ml, more preferably between 200 and 1500, most preferably between 400 and 1000 ml. Application
The infant and/or toddler nutrition according to the present invention has been found to be particularly useful as a nutrition for prematurely born babies, maturely born babies (vaginally as well as caesarean section delivered infants), infants which are in the adaptation period to solid food, infants and/or toddlers with an increased risk for or suffering from allergic eczema, from allergy, and/or infants and/or toddlers with an increased risk for infections, such as infants and/or toddlers attending day care centres, or suffering from infections. The invention is particularly advantageous for vaginally born infants. The invention is particularly advantageous for caesarean section delivered infants since these infants have an impaired microbial colonisation of the large intestine and an increased risk on development of IgE associated disorders later in life. The invention is particularly advantageous for vaginally born infants. The invention is particularly advantageous for infants suffering from allergic eczema (also referred to as atopic dermatitis, atopic eczema or allergic dermatitis) since these infants have an increased risk on development of IgE related disorders later in life.
Hence the present invention provides a method for providing nutrition to a human infant and/or toddler, said method comprising administering to the infant and/or toddler the present composition. Preferably the infant and/or toddler has an age between 0 and 36 month, more preferably between 0 and 18 month, even more preferably between 0 and 12 months, most preferably between ) and 6 months. Preferably the effect on cat allergy and/or on IgE levels is when the human subject has reached an age above 12 months, preferably above 16 month, more preferably above 24 months, more preferably above 36 months, more preferably above 5 years. Preferably the composition of the present invention is administered for a period of at least 4 weeks, more preferably at least 8 weeks, most preferably at least 12 weeks. A shorter period of administration will result in less effects later in life. In one embodiment the reduction in the increase of total serum IgE is compared to a human subject receiving the same nutritional composition without additional Bifidobacterium breve and galacto-oligosaccharide and fructo- oligosaccharide. Particularly the present invention provides a composition as described herein above accompanied with indications (e.g. written material) comprising statement that the administration of the composition (e.g. to the infant) prevents cat allergy and/or reduces serum IgE levels later in life. EXAMPLES
Example 1
Ninety full-term infants, aged 0 to 7 months, fulfilling Hanifin and Rajka criteria for atopic dermatitis, were recruited. Inclusion criteria included a SCORing Atopic Dermatitis (SCORAD) score > 15, exclusively formula fed at time of enrolment, no other major medical problems and no use of probiotics or immunomodulatory medication during the 4 weeks before enrolment. Written informed consent was obtained from both parents of all participants.
Participants were randomized, to receive as test composition an extensively hydrolyzed whey based formula (Nutrilon Pepti®, Nutricia, Zoetermeer, the Netherlands) with additional synbiotics or as placebo the same formula without synbiotics for a period of 12 weeks. The investigators, participant's own physicians and parents were all blind to the treatment groups. One year after start of the intervention period participants returned for a follow-up visit, performed by the same investigator, who was still blinded to the treatment groups. During this visit parents were asked about respiratory symptoms (cough, shortness of breath, noisy/rattly breathing, wheezing) and medication use of their child, using a validated questionnaire. Synbiotics consisted of Bifidobacterium breve M16-V, 1.3 x 10 9 cfu/100 ml and a mixture of 90% galacto-oligosaccharides (source Vivinal GOS, Borculo) and 10% fructo-oligosaccharides (source raftilin HP, Orafti), 0.8 g/100 ml. Children with an age below 6 month received starter formula. Children with an age of or above 6 month received follow on formula. Formula was given on demand.
The primary outcome measure of this randomized controlled trial, were change in severity of atopic dermatitis after 12 weeks of intervention. Respiratory outcome measures at follow-up were: 1) prevalence of respiratory symptoms predictive of asthma: frequent wheezing, defined as >3 episodes after the intervention period, and wheezing apart from colds, 2) current use of asthma medication (beta-2 agonists, anticholinergics, inhaled corticosteroids), 3) levels of IgE and presence of specific IgE (> 0.35 kU/L) against aero allergens.
At baseline and one -year follow-up total and specific serum IgE against house dust mite (dl), cat (el) and dog (e2) were determined using the CAP FEIA system (Phadia, Uppsala, Sweden). Specific IgE was considered elevated if > 0.35 kU/L. A subgroup of patients with IgE-negative AD was defined as patients with AD without elevated total and/or specific IgE levels at baseline (total IgE was considered elevated if > 5 kU/L in infants aged < 3 months and > 15 kU/L in infants aged > 3 months, reference values of the Academic Medical Center, Amsterdam).
Parametric data were analyzed with unpaired t-tests. Non-parametric data were analyzed with the Mann-Whitney U test. Binary data were analyzed using the x 2 -test, or Fisher's exact test when appropriate, and results are represented as absolute risk reduction (ARR) with 95% confidence intervals (CI). SPSS software (15.0) was used for all analyses.
Ninety infants were randomized in the original study, the intention-to-treat consisted of 85 infants, of which 75 (88%) completed the one -year follow-up evaluation. Baseline characteristics of the children (gender, age, SCORAD index, Breast fed duration, parental asthma, parental smoking, pets, day care, older siblings, probiotics use after intervention period, use of asthma medication, cough, wheezing and noisy/rattling breathing were not statistically different between the two groups. Mean age at follow-up was 17.5 months (SD 1.6) in the test group and 17.2 (SD 1.8) in the placebo group.
Frequent wheezing (> 3 episodes after the intervention period), wheezing apart from colds and wheezing and/or noisy/rattly breathing apart from colds were significantly less prevalent in the test group than in the placebo group (ARR of wheezing without colds was significant, however the P value of the χ -test was 0.056). Significantly fewer children in the test group than in the placebo group used asthma medication at time of follow-up. There were also significantly less new users of asthma medication (children that were using asthma medication at follow-up, but not at baseline) in the test group than in the placebo group. Median total serum IgE concentrations at baseline and one year follow-up are shown in Table 1. At baseline total IgE was similar in the test group and the placebo group. At follow-up total IgE was lower in the test group than in the placebo group. In the subgroup of children that were IgE- negative at baseline (n=25), total IgE at follow-up was significantly lower in the test group than in the placebo group. This effect was already observed, albeit to a lesser extent, at baseline.
The change in total serum IgE concentration between one year follow-up and baseline (AlgE) in the test group and the placebo group is also represented in table 1. In the total study population and the IgE-positive subgroup there was a tendency for a decreased AlgE between the test group and the placebo group. In the IgE-negative subgroup AlgE was statistically significantly lower in the test group than in the placebo group.
The percentage of children with elevated specific IgE against cat, dog or house dust mite at baseline and one year follow-up is represented in Table 2. At follow-up the percentage of children with positive IgE against cat was significantly lower in the test group than in the placebo group (6.9% vs. 30.3%, P = 0.03). The percentage of children with positive IgE against house dust mite (HDM) was also lower in the test group, but this difference was not statistically significant (10.3% vs. 15.2%, P = 0.71). No significant difference was observed in the percentage of children with positive IgE against dog allergen.
In conclusion, it was demonstrated that infants that received B. breve for a period of 3 months, had a lower prevalence of cat allergy and a reduced increase in IgE, especially in infants being IgE negative at baseline, at one -year follow-up than those who received placebo.
Table 1. Total IgE levels and change in total IgE concentration
ANCOVA analysis with baseline Box-Cox transformation
Wilcoxon-Mann-Whitney test Table 2. Proportion of positive infants for total and specific IgE (> 0.35 kU/L) at baseline, week 12, and follow up in the test group and place (control) group (%).
Fisher Exact test
Next Patent: ASSEMBLY FOR TAKING UP MENSTRUAL FLUID